| (Values in U.S. Thousands) | Apr, 2025 | Apr, 2024 | Apr, 2023 | Apr, 2022 | Apr, 2021 |
| Sales | 1,707,920 | 1,705,000 | 1,614,360 | 1,638,110 | 1,574,490 |
| Sales Growth | +0.17% | +5.61% | -1.45% | +4.04% | +3.89% |
| Net Income | 22,370 | 122,520 | 90,250 | 129,940 | 143,460 |
| Net Income Growth | -81.74% | +35.76% | -30.54% | -9.42% | +27.50% |
Elekta B Shs ADR (EKTAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company's offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden.
Fiscal Year End Date: 04/30